Trials / Completed
CompletedNCT04557163
Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-center, single-sequence study to evaluate the concomitant effects of the potent CYP3A inhibitor itraconazole on the single-dose pharmakokinetics, safety and tolerability of oral TS-142 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-142 | TS-142 will be given as 1 mg per capsule administered orally with water. |
| DRUG | Itraconazole | Itraconazole will given as 50 mg per capsule administered orally with water. |
Timeline
- Start date
- 2020-10-13
- Primary completion
- 2020-11-14
- Completion
- 2020-11-14
- First posted
- 2020-09-21
- Last updated
- 2025-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04557163. Inclusion in this directory is not an endorsement.